Denali Therapeutics (DNLI) Financials: History & Chart

Denali Therapeutics Inc.(DNLI)

Biotechnology · South San Francisco, CA

$19.72-0.19 (-0.95%)

Delayed quote: Oct 6, 2026, 12:20 PM EDT

About Denali Therapeutics Inc.

Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.

South San Francisco, CA

503 employees

www.denalitherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Ryan J. Watts

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	3.60M	3.60M	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cost of Goods Sold	5.80M	93K	2.85M	2.87M	0.00	0.00	0.00	0.00	0.00
Gross Profit	-2.20M	3.51M	-2.85M	-2.87M	0.00	0.00	0.00	0.00	0.00
Gross Profit Margin	-61.0%	97.4%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Operating Expenses	540.50M	134.05M	134.51M	134.50M	137.43M	134.96M	145.58M	129.85M	123.19M
Research & Development	400.72M	97.02M	103.85M	97.91M	101.95M	102.70M	116.23M	99.79M	98.24M
Selling, General & Administrative	139.03M	36.28M	30.67M	36.59M	35.48M	32.27M	29.35M	30.06M	24.95M
Operating Income (EBIT)	-542.70M	-130.54M	-137.36M	-137.37M	-137.43M	-134.96M	-145.58M	-129.85M	-123.19M
Operating Margin	-15058.2%	-3622.1%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Before Tax (EBT)	-511.35M	-127.55M	-128.45M	-128.45M	-126.90M	-124.12M	-132.97M	-114.69M	-107.19M
Interest Income	28.36M	N/A	8.91M	8.92M	10.53M	10.84M	12.61M	15.16M	15.99M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	31.35M	2.99M	8.91M	8.92M	10.53M	10.84M	12.61M	15.16M	15.99M
Net Income	-511.45M	-127.55M	-128.45M	-128.55M	-126.90M	-124.12M	-132.97M	-114.75M	-107.19M
Income Tax Expense	102K	0.00	0.00	102K	0.00	0.00	0.00	68K	0.00
Net Profit Margin	-14191.2%	-3539.2%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EBITDA	-528.64M	-126.97M	-134.51M	-133.58M	-133.57M	-131.01M	-142.37M	-127.23M	-120.92M
EBITDA Margin	-14668.1%	-3523.1%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Depreciation & Amortization	14.06M	3.57M	2.85M	3.78M	3.86M	3.96M	3.21M	2.62M	2.27M
EPS Basic	-2.84	-0.68	-0.69	-0.73	-0.74	-0.72	-0.78	-0.67	-0.63
EPS Diluted	-2.84	-0.68	-0.69	-0.73	-0.74	-0.72	-0.78	-0.67	-0.63
Weighted Average Basic Shares	187.31M	187.31M	186.64M	175.46M	172.42M	171.45M	171.22M	170.09M	169.46M
Weighted Average Diluted Shares	187.31M	187.31M	186.64M	175.46M	172.42M	171.45M	171.22M	170.09M	169.46M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	0.00	0.00	330.53M	108.46M	48.66M	335.66M	26.68M	129.16M
Cost of Goods Sold	11.18M	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-11.18M	0.00	330.53M	108.46M	48.66M	335.66M	26.68M	129.16M
Gross Profit Margin	N/A	N/A	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Total Operating Expenses	544.16M	487.34M	527.23M	449.21M	344.41M	272.94M	239.86M	175.53M
Research & Development	418.78M	396.44M	423.88M	358.73M	265.35M	212.62M	193.38M	143.18M
Selling, General & Administrative	97.10M	105.44M	103.35M	90.47M	79.06M	60.33M	46.48M	32.35M
Operating Income (EBIT)	-555.34M	-487.34M	-196.70M	-340.74M	-295.75M	62.72M	-213.18M	-46.37M
Operating Margin	N/A	N/A	-59.5%	-314.2%	-607.8%	18.7%	-799.1%	-35.9%
Income Before Tax (EBT)	-512.44M	-422.70M	-145.19M	-325.97M	-291.16M	71.96M	-197.97M	-36.24M
Interest Income	42.90M	64.64M	51.51M	14.77M	4.59M	9.24M	15.22M	10.13M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	42.90M	64.64M	51.51M	14.77M	4.59M	9.24M	15.22M	10.13M
Net Income	-512.54M	-422.77M	-145.22M	-325.99M	-290.58M	71.14M	-197.61M	-36.24M
Income Tax Expense	102K	68K	30K	21K	-575K	823K	-351K	0.00
Net Profit Margin	N/A	N/A	-43.9%	-300.6%	-597.2%	21.2%	-740.7%	-28.1%
EBITDA	-540.53M	-478.35M	-179.97M	-330.36M	-287.16M	71.25M	-205.19M	-38.96M
EBITDA Margin	N/A	N/A	-54.4%	-304.6%	-590.1%	21.2%	-769.1%	-30.2%
Depreciation & Amortization	14.81M	8.99M	16.73M	10.38M	8.59M	8.53M	7.99M	7.42M
EPS Basic	-2.97	-2.57	-1.06	-2.60	-2.39	0.65	-2.07	-0.39
EPS Diluted	-2.97	-2.57	-1.06	-2.60	-2.39	0.63	-2.07	-0.39
Weighted Average Basic Shares	175.46M	164.47M	137.37M	125.53M	121.52M	108.97M	95.61M	92.62M
Weighted Average Diluted Shares	175.46M	164.47M	137.37M	125.53M	121.52M	112.70M	95.61M	92.62M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.